The FDA on December 27, 2024, approved OPDIVO QVANTIG® for subcutaneous injection across approved adult, solid tumor OPDIVO® indications as monotherapy, monotherapy maintenance following completion of OPDIVO® plus YERVOY® (Ipilimumab) combination therapy, or in combination with chemotherapy or Cabozantinib. OPDIVO QVANTIG® is a product of Bristol Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
